Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
443
NCT03531060
A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Phase: Phase 1/2
Role: Lead Sponsor
Start: Nov 8, 2016
Completion: Apr 12, 2017
NCT03368170
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Phase: Phase 2
Start: Apr 12, 2018
Completion: Jun 12, 2019
NCT04435431
A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
Start: Oct 29, 2020
Completion: Dec 9, 2022
NCT05258071
A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients with Parkinson's Disease (PD)
Start: Jun 15, 2022
Completion: Jan 9, 2025
NCT06493045
First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
Phase: Phase 1
Start: May 16, 2024
Completion: Feb 7, 2025
NCT06699628
Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers
Start: Sep 23, 2024
Completion: Nov 11, 2024